Journal of Clinical Toxicology
Open Access

The efficacy of doxocycline, rousovastatine and spironolactone on cardiotoxic effect of Doxorubicin in female albino rats

6^th Global Summit on Toxicology & Applied Pharmacology

October 17-19, 2016 Houston, USA

Ansam Jalal Aram Altelchy and Ansam N Al-Hassani

Hawler Medical University, Iraq

Posters & Accepted Abstracts: J Clinic Toxicol

Abstract :

Background: Cardiotoxicity that caused by chemotherapy is a devastating disorder that impairs the ability of the heart to respond to physiological demands for increased cardiac output that may result in heart failure. Thus it led to the attempt to evaluate the efficacy of Doxycycline, Rosuvastatin and spironolacton in doxorubicin induced cardiotoxicity. Aims of this study: To assess the ability of these drugs to attenuate doxorubicin induced Heart Failure in Rats and to compare among them regarding their ability to cause remarkable structural, biochemical, and histopathological changes that preserve normal cardiac function. Methods: 46 female Albino Rats, 8-12 weeks old, were used in the study. They were divided in to 3 groups. The control group, Doxorubicin group and treatment group. All groups were treated for a period of 4 weeks. Mean serum (BNP), (CgA), (TC), (HDL), (LDL), (TG) and (UA) levels, in addition to the histopathological studies, are the estimated parameters used in this study. Results: All drugs used in the treatment group showed a degree of cardioprotection effect againist doxorubicin induced cardiotoxicity and caused a significant reduction in mean serum BNP, CgA, Total cholesterol, TG, LDL, and Uric acid levels and increment in HDL as compared with Doxo group while Spironolactone appeared to be inferior in amelioration those parameters than the other drugs in the treatment group. Conclusion: Rosuvastatine appeared to be the most beneficial in amelioration doxorubicin induced cardiac toxicity.

Biography :

Email: ansam_pharma@yahoo.com